Solcoseryl solution for injections 42,5mg/ml, 5ml – 5 ampoules
Manufacturer: Meda Pharma GmbH and Co., Switzerland
1 ml of the solution contains:
Active substance: deproteinized dialysate obtained from the blood of healthy veal calves, chemically and biologically standardized (on the moisture-free basis) 42,5 mg;
Additive agents: water for injections — to 1 ml.
Solcoseryl is a stimulant of skin regeneration. It is deproteinized dialysate obtained from the blood of veal calves containing a wide range of low-molecular components of the cell pellet and whey with a molecular mass of 5000 D (including glycoproteids, nucleosides and nucleotides, amino acids, oligapeptides).
Solcoseryl enhances oxygen and glucose transport to the cells under conditions of hypoxia, increases the synthesis of intracellular adenosine triphosphate and contributes to an increase in the dose of aerobic glycolysis and oxidative phosphorylation, promotes reparative and regenerative processes in tissues, stimulates proliferation of fibroblasts and synthesis of vascular wall collagen.
Indications for use:
- Disturbance of peripheral arterial or venous circulation:
III-IV stages occlusal peripheral artery diseases according to the Fontaine classification;
- chronic venous insufficiency accompanied by trophic disturbances.
- metabolism and blood circulation disturbance:
- ischemic stroke;
- hemorrhagic stroke;
- head injuries.
Using during pregnancy and breastfeeding:
The use of Solcoseryl like all other medicines is undesirable across pregnancy and lactation period and possible only in case of extreme necessity and under the care of a doctor.
- childhood and teenage age to 18 years (no data on the safe use);
- pregnancy (no data on the safe use);
- lactation (no data on the safe use);
- established hypersensitivity to calf blood dialysates;
- hypersensitivity to para-hydroxybenzoic acid derivatives (Е216 and Е218) and free benzoic acid (Е210).
Care must be taken with taking this drug in hyperkalemia, renal insufficiency, heart rhythm disorder, accompanying contact with potassium preparations (since Solcoseryl contains potassium), in oliguria, anuresis, pulmonary edema, acute heart failure.
An allergic response can rarely develop (hives, hyperaemia and edema in the sites of injection, temperature rise). In this case, you should stop taking the drug and prescribe symptomatic treatment.
Solcoseryl injections shouldn’t be mixed when injecting with other medical products, particularly — with phytoextracts.
The pharmaceutical incompatibility of Solcoseryl in the forms of solution for injections is established with the parenteral forms of:
- Ginkgo biloba extract,
- fumarate bencyclane.
As the assay diluent of Solcoseryl injections only sodium chloride isotonic solution and 5% glucose solution should be used.
The interaction of Solcoseryl with other medicinal products of topical action is not established.
How to use, administration course and dosage:
Intravenously or intramuscularly:
When treating III-IV stages occlusal diseases of peripheral arteries according to the Fontaine classification – I.V. by 20 ml every day. Intravenous drip infusion in the isotonic solution of sodium chloride or 5% glucose solution is possible.
When treating chronic venous insufficiency accompanied by trophic disturbances (Ulcera cruris) — I.V. by 10 ml 3 times a week.
Therapy duration — no more than 4 weeks and is defined by the clinical findings of the disease. Dressing of a compressive bandage with the use of an elastic roller is also an important measure aimed at the prevention of peripheral “venous” edemas.
In the presence of the local trophical disturbances of tissues, therapy with Solcoseryl jelly and then Solcoseryl ointment is recommended.
When treating ischemic and hemorrhagic strokes of severe and extremely severe form as the basic course – I.V. by 10 or 20 ml correspondingly, every day by 10 days. Upon completion of the basic course – I.M. or I.V. by 2 ml within 30 days.
Head injury (severe brain contusion) — I.V. 1000 mg, every day within 5 days.
If intravenous administration of the drug is not impossible, the drug can be injected intramuscularly, usually by 2 ml a day in the undiluted form.
When injecting the undiluted solution intravenously, it should be injected slowly since it is a hypertonic solution.
In case of pain sense, reddening of skin areas next to the spots of Solcoseryl application, secreting from the wound, temperature rise, one should immediately see a doctor.
If when using Solcoseryl within 2–3 weeks the healing of the damaged area is not observed, one should see a doctor.
Pharmaceutical form: Solution for injection.
Storage conditions: In a place protected from light, at a temperature of not above 25 °C.
Shelf life: 5 years.
Active substance: Deproteinized dialysate obtained from calf blood.
Pharmacy purchasing terms: Without a prescription.